GR1802 not checked
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Recombinant fully human anti-IL4Rα monoclonal antibody drug.”In the company’s words, NCT07154342 on ClinicalTrials.gov
- Tested for
- Allergic Rhinitis, Seasonal (2 trials), Allergic Rhinitis
- Main trialPhase 3
- “Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies.”In the company’s words, NCT07154342 on ClinicalTrials.gov
Other drugs for Allergic Rhinitis, Seasonal
- SHR-1819Hengrui · Phase 3
- StapokibartKeymed Biosciences Co.Ltd · Phase 3
- Rupatifen FumarateFujian Mindong Rejuvenation Pharmaceutical Co., Ltd. · Phase 3
- LP-003Longbio Pharma · Phase 3
- MG-K10Shanghai Mabgeek Biotech.Co.Ltd · Phase 2/3
- PG-011Prime Gene Therapeutics Co., Ltd. · Phase 3
Coming up1
- 15 May 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Apr 2026 | A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis | |
| Phase 3Not yet recruiting | 15 May 2027 | A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis. | |
| Phase 2Active, not recruiting | May 2025 | A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR). | |
| Phase 3Unknown | Jun 2025 | Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis | |
| Phase 3Completed | 12 Jun 2026 | A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps | |
| Phase 2Unknown | 30 Oct 2024 | The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps | |
| Phase 2Unknown | 30 Dec 2024 | The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps | |
| Phase 2Unknown | 31 Mar 2025 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026